ProSomnus CEO Len Liptak unveils game-changing device and promising clinical trial results for 2024
–News Direct–
ProSomnus Inc CEO Len Liptak joined Steve Darling from Proactive to discuss the company's groundbreaking intramural mouth guard, which has received FDA clearance as a medical device for the treatment of obstructive sleep apnea and snoring.
The ProSomnus device effectively positions the jaw forward during sleep, preventing airway collapse and addressing sleep apnea issues.
Liptak emphasized the significance of the FDA clearance, which allows for insurance reimbursement and categorizes the ProSomnus device as a therapeutic solution for sleep apnea and snoring.
The company is strategically targeting the substantial market of individuals who discontinue the use of CPAP (Continuous Positive Airway Pressure) machines, estimated at 3 to 4 million people annually. In lig...